Icotinib Hydrochloride in Treating Patients With Advanced Cancers

Summary

This phase I trial studies the side effects and best dose of icotinib hydrochloride in treating patients with advanced cancers. Icotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2014-08

Primary completion

2016-06

Completion

—

Outcome

Outcome not reported

Stopped: “changes in study design by sponsor not acceptable for participating”

Drugs

Indications